Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

, SNY

Sanofi

$43.09

-0.83 (-1.89%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04

Alnylam announces lift of FDA clinical hold on Fitusiran

Alnylam Pharmaceuticals (ALNY) and Sanofi Genzyme, the specialty care global business unit of Sanofi (SNY), announced today that the U.S. Food and Drug Administration has lifted the hold on clinical studies with fitusiran, including the Phase 2 open-label extension study and the ATLAS Phase 3 program. Alnylam and the FDA had previously reached alignment on new clinical risk mitigation measures, including protocol-specified guidelines and additional investigator and patient education concerning reduced doses of replacement factor or bypassing agent to treat any breakthrough bleeds in fitusiran studies. The FDA has now approved the protocol amendments and other updated clinical materials for fitusiran studies. Fitusiran is an investigational RNAi therapeutic targeting antithrombin for the treatment of patients with hemophilia A and B. It is designed to lower levels of AT with the goal of promoting sufficient thrombin generation to restore hemostasis and prevent bleeding.

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

SNY

Sanofi

$43.09

-0.83 (-1.89%)

  • 18

    Jan

  • 25

    Mar

  • 02

    May

ALNY Alnylam
$123.66

-1.2 (-0.96%)

11/03/17
COWN
11/03/17
NO CHANGE
Target $151
COWN
Outperform
Alnylam price target raised to $151 from $117 at Cowen
Cowen analyst Ritu Baral raised her price target on Alnylam to $151 from $117 following its presentation of full data from the Phase 3 APOLLO trial of patisiran. The data showed benefits in cardiac measure and excellent safety and approval should be expected in 2018 with a broad label. Baral reiterated her Outperform rating on Alnylam shares.
11/08/17
LEHM
11/08/17
NO CHANGE
Target $158
LEHM
Overweight
Alnylam price target raised to $158 from $127 at Barclays
Barclays analyst Gena Wang raised her price target for Alnylam Pharmaceuticals to $158 saying the company highlighted multiple pipeline progresses during the Q3 earnings call. The analyst keeps an Overweight rating on the shares.
11/09/17
JPMS
11/09/17
UPGRADE
Target $162
JPMS
Overweight
Alnylam upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Alnylam Pharmaceuticals saying he believes patisiran "has definitively solidified" a dominant market position in the ATTR amyloidosis space. The analyst expects a "smooth regulatory process" for patisiran and broad label enabling use in the mutant mixed FAC phenotype. Rama raised his price target for Alnylam shares to $162 from $86.
11/17/17
PIPR
11/17/17
NO CHANGE
Target $182
PIPR
Overweight
Piper trims Alnylam target to $182 after capital raise
Piper Jaffray analyst Edward Tenthoff trimmed his price target for Alnylam Pharmaceuticals to $182 from $188 to account for dilution from the company's issuance of 6.44M shares at $125. The company's cash position of $1.93B will allow for the patisiran launch and pipeline advancements, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Alnylam.
SNY Sanofi
$43.09

-0.83 (-1.89%)

11/15/17
LEHM
11/15/17
UPGRADE
LEHM
Equal Weight
Sanofi upgraded to Equal Weight from Underweight at Barclays
Barclays upgraded Sanofi to Equal Weight from Underweight saying valuation is back to more reasonable levels.
11/16/17
EVER
11/16/17
NO CHANGE
Target $445
EVER
Outperform
Regeneron price target lowered to $445 from $605 at Evercore ISI
Evercore ISI lowered its price target for Regeneron (REGN) to $445 from $605 given meaningful competitive threat to Eylea. For every dollar of U.S. Eylea sales lost to competition, Regeneron has to make up for it with two times as much revenue from the Sanofi (SNY) JV, it adds. The firm has an Outperform rating on Regeneron's shares.
12/01/17
MSCO
12/01/17
DOWNGRADE
MSCO
Underweight
Sanofi downgraded to Underweight from Overweight at Morgan Stanley
12/06/17
BOFA
12/06/17
DOWNGRADE
BOFA
Neutral
Sanofi downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Graham Perry downgraded Sanofi to Neutral citing valuation and lack of earnings momentum into 2018.

TODAY'S FREE FLY STORIES

VLRX

Valeritas

$1.52

-0.05 (-3.18%)

07:06
05/23/18
05/23
07:06
05/23/18
07:06
Hot Stocks
Valeritas' V-Go device shows benefits in type 2 diabetes »

Valeritas announced data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$70.40

-1.35 (-1.88%)

07:05
05/23/18
05/23
07:05
05/23/18
07:05
Hot Stocks
Cubic's CTS unit awarded contract from SRTA in Atlanta »

Cubic Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

TGT

Target

$75.42

-1.44 (-1.87%)

07:05
05/23/18
05/23
07:05
05/23/18
07:05
Technical Analysis
Technical Take: Target falls sharply after earnings miss »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 19

    Jun

REX

REX American Resources

$76.62

-0.5 (-0.65%)

07:05
05/23/18
05/23
07:05
05/23/18
07:05
Earnings
REX American Resources reports Q1 EPS $1.45 vs. 69c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ALKS

Alkermes

$45.58

0.35 (0.77%)

07:04
05/23/18
05/23
07:04
05/23/18
07:04
Hot Stocks
Alkermes to present data on depression, schizophrenia portfolios at ASCP »

Alkermes announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    Jan

KOOL

Cesca Therapeutics

$0.53

0.0307 (6.14%)

07:04
05/23/18
05/23
07:04
05/23/18
07:04
Initiation
Cesca Therapeutics initiated  »

Cesca Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCI

Navigant Consulting

$24.00

-0.19 (-0.79%)

07:04
05/23/18
05/23
07:04
05/23/18
07:04
Hot Stocks
Navigant Consulting, Lumere announce collaboration to reduce clinical variation »

Navigant Consulting and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

ACRX

AcelRx

$2.95

0.05 (1.72%)

07:03
05/23/18
05/23
07:03
05/23/18
07:03
Hot Stocks
Three Arch's shares of AcelRx stock acquired in deal led by Leerink Revelation »

AcelRx Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:02
05/23/18
05/23
07:02
05/23/18
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 5/18 MBA Mortgage…

ANTM

Anthem

$234.12

0.52 (0.22%)

07:02
05/23/18
05/23
07:02
05/23/18
07:02
Hot Stocks
Anthem to acquire Aspire Health, financial terms not disclosed »

Anthem announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MINE

Minerco Resources

$0.00

(0.00%)

07:02
05/23/18
05/23
07:02
05/23/18
07:02
Hot Stocks
Minerco acquires controlling interest in Priwen Systems »

Minerco announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XCRA

Xcerra

$14.01

0.31 (2.26%)

07:02
05/23/18
05/23
07:02
05/23/18
07:02
Earnings
Xcerra reports Q3 non-GAAP EPS 24c, consensus 20c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

SO

Southern Company

$43.55

0.13 (0.30%)

07:01
05/23/18
05/23
07:01
05/23/18
07:01
Hot Stocks
Southern Power to sell minority stake in solar portfolio for $1.175B to GAFG »

Southern Power, a U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SPX

S&P 500

$0.00

(0.00%)

07:00
05/23/18
05/23
07:00
05/23/18
07:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.33

-0.02 (-0.06%)

07:00
05/23/18
05/23
07:00
05/23/18
07:00
Hot Stocks
Aecom awarded 15-year $3.1B U.S. Air Force contract »

AECOM's wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$177.66

0.08 (0.05%)

, CVS

CVS Health

$65.59

0.09 (0.14%)

06:58
05/23/18
05/23
06:58
05/23/18
06:58
Recommendations
Aetna, CVS Health analyst commentary  »

Aetna risk/reward…

AET

Aetna

$177.66

0.08 (0.05%)

CVS

CVS Health

$65.59

0.09 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

FTR

Frontier Communications

$9.55

-0.06 (-0.62%)

06:58
05/23/18
05/23
06:58
05/23/18
06:58
Periodicals
Frontier in talks with bondholders after failed asset auction, Bloomberg reports »

Frontier Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$39.46

-4.14 (-9.50%)

06:55
05/23/18
05/23
06:55
05/23/18
06:55
Recommendations
Toll Brothers analyst commentary  »

Toll Brothers price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$183.81

-0.67 (-0.36%)

06:53
05/23/18
05/23
06:53
05/23/18
06:53
Periodicals
Facebook's upper ranks never seem to leave company, Recode reports »

Facebook's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

TIF

Tiffany

$102.26

-0.96 (-0.93%)

06:52
05/23/18
05/23
06:52
05/23/18
06:52
Hot Stocks
Breaking Hot Stocks news story on Tiffany »

Tiffany up 7.8% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 26

    Jun

REGN

Regeneron

$294.72

-1.86 (-0.63%)

, SNY

Sanofi

$38.93

0.15 (0.39%)

06:52
05/23/18
05/23
06:52
05/23/18
06:52
Recommendations
Regeneron, Sanofi analyst commentary  »

Regeneron product…

REGN

Regeneron

$294.72

-1.86 (-0.63%)

SNY

Sanofi

$38.93

0.15 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Aug

  • 20

    Oct

  • 28

    Jan

MRK

Merck

$58.46

-0.1 (-0.17%)

06:52
05/23/18
05/23
06:52
05/23/18
06:52
Hot Stocks
Merck announces Keytruda met the dual primary endpoints in KEYNOTE trial »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

  • 23

    Oct

TIF

Tiffany

$102.26

-0.96 (-0.93%)

06:51
05/23/18
05/23
06:51
05/23/18
06:51
Earnings
Tiffany raises FY18 EPS view to $4.50-$4.70, consensus $4.42 »

Management's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 26

    Jun

GDX

Market Vector Gold Miners

$22.12

-0.22 (-0.98%)

06:51
05/23/18
05/23
06:51
05/23/18
06:51
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$122.42

-0.05 (-0.04%)

06:50
05/23/18
05/23
06:50
05/23/18
06:50
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.